Cocaine use disorder drug pipeline
- ICD-11 6C45
- MeSH D019970
- Subtype of Stimulant use disorder
2 compounds from 2 companies are in active clinical development for cocaine use disorder.
Mechanisms: Small molecule (2)
Pipeline data compiled October 2026 · every fact sourced.
Upcoming readouts & recent results
Phase 2 EMB-001 in cocaine use disorder misses primary endpoint: continuous abstinence weeks 11-13 in 2/41 (EMB-001) vs 0/41 (placebo), p=0.092. ↗
Phase 2 full results published in Science Translational Medicine: mavoglurant reduced cocaine use versus placebo in 68 adults with cocaine use disorder (NCT03242928), the evidence base for Stalicla's planned Phase 3. ↗
Compounds in development (2)
| Compound | Company | Phase | Status | Mechanism |
|---|---|---|---|---|
| EMB-001 (metyrapone/oxazepam) | Embera NeuroTherapeutics, Inc. | Phase 2 | Unknown | CYP11B1 Inhibitor |
| Mavoglurant | Stalicla SA | Phase 2 | Active | mGlu5 NAM |
Trials recruiting now (10)
10 drug-interventional cocaine use disorder trials recruiting now, of 98 registered interventional trials. Browse all on ClinicalTrials.gov →
clonidine, clonazepam 0,25 mg
Sustained-release Dexamphetamine, Placebo
Semaglutide, Placebo
Semaglutide, Placebo
Ketamine, Placebo
Cobenfy, Placebo
Placebo, Cocaine (IV), Pentoxifylline
d-amphetamine
Hydrocortisone
4-aminopyridine (4-AP), Placebo
Frequently asked
- How many drugs are in development for cocaine use disorder?
- 2 compounds from 2 companies are in active clinical development for cocaine use disorder.
- How many clinical trials are recruiting for cocaine use disorder?
- 10 drug-interventional cocaine use disorder trials are currently recruiting participants, out of 98 registered interventional trials.